December 26, 2018 / 11:28 AM / 6 months ago

Capricor places Duchenne drug trial on hold

Dec 26 (Reuters) - Capricor Therapeutics Inc said on Wednesday it had put on hold a clinical trial of its drug to treat Duchenne muscular dystrophy, a muscle-wasting disorder.

The hold was due to an ongoing safety review following severe allergic reaction that occurred during the trial, the company said in a filing. (Reporting by Manas Mishra in Bengaluru; Editing by Anil D'Silva)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below